Travere Therapeutics (TVTX) operating margin
Travere Therapeutics (TVTX) had an operating margin of -12.8% in fiscal 2025 (the year ended December 31, 2025). That is 97.1 percentage points higher than the -109.9% of fiscal 2024. Figures as of 17 Nov 2026, 22:43 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- Operating margin, fiscal 2025
- -12.8%
- Change on fiscal 2024
- +97.1 pts
- Highest on record
- -12.8%fiscal 2025
- Lowest on record
- -292.2%fiscal 2022
- Fiscal years on record
- 122014–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Travere Therapeutics operating margin, in more detail
Across the 12 fiscal years on record (2014–2025), the highest was -12.8% in fiscal 2025 and the lowest -292.2% in fiscal 2022. The fiscal 2025 figure is higher than in every one of the 11 earlier fiscal years on record, whose median is -88.8%.
Gross margin was 97.9% in fiscal 2025. Net margin was -5.2% in fiscal 2025.
Operating margin by fiscal year
- Operating margin
- Gross margin
- Net margin
Travere Therapeutics operating margin, year by year
| Fiscal year | Operating margin | Change | Year ended | Gross margin | Net margin |
|---|---|---|---|---|---|
| 2025 | -12.8% | 97.1 pts up | 97.9% | -5.2% | |
| 2024 | -109.9% | 149.5 pts up | 96.7% | -137.9% | |
| 2023 | -259.4% | 32.8 pts up | 92.1% | -76.7% | |
| 2022 | -292.2% | 140.9 pts down | 96.0% | -254.4% | |
| 2021 | -151.3% | 62.4 pts down | — | -136.6% | |
| 2020 | -88.8% | 10.5 pts down | — | -85.4% | |
| 2019 | -78.3% | 29.6 pts down | — | -83.5% | |
| 2018 | -48.7% | 14.0 pts down | — | -62.5% | |
| 2017 | -34.7% | 8.9 pts up | — | -38.6% | |
| 2016 | -43.6% | 7.2 pts up | — | -35.9% | |
| 2015 | -50.8% | 232.2 pts up | — | 117.4% | |
| 2014 | -283.0% | — | — | -393.4% |
Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.
How to read it
It shows how much of each unit of sales survives the cost of running the business — rising margins point to pricing power or scale, falling ones to pressure.
Operating margin at health care companies of similar size
| Company | Operating margin | Fiscal year |
|---|---|---|
| MiniMed Group MMED | -5.1% | 2026 |
| Adaptive Biotechnologies ADPT | -20.6% | 2025 |
| Heartflow HTFL | -36.4% | 2025 |
| CRISPR Therapeutics CRSP | -1333.0% | 2024 |
| Travere Therapeutics TVTX | -12.8% | 2025 |
| Option Care Health OPCH | 6.0% | 2025 |
The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.
Travere Therapeutics, figure by figure
- Travere Therapeutics market cap
- Travere Therapeutics revenue
- Travere Therapeutics earnings
- Travere Therapeutics earnings per share (EPS)
- Travere Therapeutics P/E ratio
- Travere Therapeutics P/S ratio
- Travere Therapeutics P/B ratio
- Travere Therapeutics free cash flow
- Travere Therapeutics dividend
- Travere Therapeutics shares outstanding
- Travere Therapeutics total debt
- Travere Therapeutics cash on hand
- Travere Therapeutics total assets
- Travere Therapeutics return on equity (ROE)
- Travere Therapeutics return on invested capital (ROIC)
Travere Therapeutics (TVTX) overview: price, valuation and scorecardAll health care companies by market value
Travere Therapeutics operating margin: questions and answers
What is Travere Therapeutics's operating margin?
Travere Therapeutics (TVTX) had an operating margin of -12.8% in fiscal 2025 (the year ended December 31, 2025). That is 97.1 percentage points higher than the -109.9% of fiscal 2024.
Is Travere Therapeutics's operating margin high or low compared with its own history?
The fiscal 2025 figure is higher than in every one of the 11 earlier fiscal years on record, whose median is -88.8%.
What are the highest and lowest operating margin figures on record for Travere Therapeutics?
Across the 12 fiscal years on record (2014–2025), the highest was -12.8% in fiscal 2025 and the lowest -292.2% in fiscal 2022.
What are Travere Therapeutics's gross and net margins?
Gross margin was 97.9% in fiscal 2025. Net margin was -5.2% in fiscal 2025.
How is Travere Therapeutics's operating margin calculated?
Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.
Fiscal years are named for the calendar year they end in.
Learn: operating margin
All stocks guides →- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
Cite this page
Funkfolio, “Travere Therapeutics (TVTX) operating margin”, data as of 17 November 2026. https://funkfolio.com/stock/TVTX/operating-margin
Underlying data: the company's filings with the SEC and Yahoo Finance.